Translation of survival benefits observed in glioblastoma clinical trials to populations and to
longer-term survival remains uncertain. We aimed to assess if≥ 2-year survival has …

Gliomas are the most common primary intracranial tumor, representing 81% of malignant
brain tumors. Although relatively rare, they cause significant mortality and morbidity …

Background CBTRUS is currently the only population-based site-specific registry in the US
that works in partnership with a public cancer surveillance organization, the CDC's NPCR …

Radiographic endpoints including response and progression are important for the
evaluation of new glioblastoma therapies. The current RANO criteria was developed to …

Drug delivery into the brain is regulated by the blood–brain interfaces. The blood–brain
barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid …

BACKGROUND: Survival after a glioblastoma multiforme (GBM) diagnosis remained static
during the several decades before 1999. We hypothesized that the progressive increase in …

BACKGROUND AND PURPOSE: Tumor location is a significant prognostic factor in
glioblastoma, which may reflect the genetic profile of tumor precursor cells. The purpose of …

Primary central nervous system tumors (PCNST) are rare tumors responsible for high
mortality and morbidity. Their epidemiology is poorly known, and clinical data are scarcely …

Gliomas are the most malignant brain tumors, and their treatment is very challenging
because of the presence of the blood–brain barrier (BBB). Intranasal administration has …

Cellular energy metabolism is one of the main processes affected during the transition from
normal to cancer cells, and it is a crucial determinant of cell proliferation or cell death. As a …